Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genetic Technologies Limited (GENE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2800+0.0400 (+3.23%)
At close: 03:58PM EDT
1.2800 0.00 (0.00%)
After hours: 06:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2400
Open1.2900
Bid1.2500 x 1200
Ask1.3000 x 900
Day's Range1.2500 - 1.2900
52 Week Range0.9500 - 4.5900
Volume30,781
Avg. Volume47,883
Market Cap21.454M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.6000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer Risk Assessment Test

    MELBOURNE, Australia, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the completion of an independently developed and validated customizable Budget Impact Model (BIM), which demonstrates significant health and economic benefits directly attributed to the implementation of geneType Breast Cancer Risk Assessment Test. Breast cancer ri

  • GlobeNewswire

    Acquisition of global direct to consumer ecommerce business

    MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor

  • GlobeNewswire

    Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

    MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re

Advertisement
Advertisement